|
Biovail buys Prestwick for $100M
PE Week
September 29, 2008Biovail Corp. (NYSE: BVF) has acquired Prestwick Pharmaceuticals Inc., a Washington, D.C.-based drug company focused on central nervous system disorders, for $100 million in cash. Prestwick had raised about $120 million in total venture funding since 2002 from Atlas Venture, Pequot Ventures, Scale Venture Partners, Sofinnova Ventures, Vivo Ventures and Warburg Pincus.
|
